Scandinavian ChemoTech welcomes new strength to the management team
Scandinavian ChemoTech announces that Ulf Lundgren, responsible for QA / RA, has chosen to unwind and complete his assignment and will be replaced by Eva Ståhl Wernersson.
Eva Ståhl Wernersson, will on April 19 succeed Ulf in the role of Director of Quality Management & Regulatory Affairs, which i.e., entails responsibility for CE marking and quality systems. Eva has a master's degree in chemical engineering and has a doctorate in food technology and has a long career in medical technology, but has also worked in various manufacturing companies with development and quality. Since the late summer of 2020, Eva has had the overall responsibility for the CE marking of the company's unique and patented TSE platform. Eva has, among others. a. since 2017 responsible for a successful CE marking for Pharmiva, a position she will end on 14 April.
“I would like to thank Ulf Lundgren for his contribution and commitment during his years at ChemoTech. His broad knowledge and experience have created an important base in ChemoTech's business. We wish Ulf all the best in the future,” says Mohan Frick, CEO of Scandinavian ChemoTech
“Even though Eva has worked with us since the middle of last year, we would like to take this opportunity to welcome her as QM / RA Director and welcome to the company's management team. With her broad competence and long experience in medical technology, Eva will be an important part of ChemoTech's new phase. ”- says Mohan Frick
“I look forward to working with an essential medical technology product, which is used to reduce the effects and suffering of various cancers, from a regulatory and quality perspective. Since the summer of last year, I have experienced the company's team spirit, which is driving, inclusive and supportive.” - says Eva Ståhl Wernersson
Eva Ståhl Wernersson holds 12,000 Series B shares in ChemoTech and completed her last purchase on March 26, 2021.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-04-2021 10:30 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
